The New York State Department of Health had previously provided conditional approval of the microRNA classifier for diagnosing indeterminate thyroid cancer cases.
The company missed analyst estimates on the top line, but beat expectations for loss per share during the quarter.
After a 54 percent quarter over quarter rise in sales of the test, Rosetta's CEO said that the realigned strategy will take the firm to profit more quickly.
MultiGen said its test identified and confirmed the BRAF p.V600E mutation with a thousandfold increase in sensitivity compared to competing PCR-based and NGS methods.
The test, intended as an aid for diagnosing thyroid cancer where cytopathology is inconclusive, is now covered for around 250 million patients nationwide.
In PLOS this week: selective constraint within aspen tree buds, bird phylogenetic diversity varies by latitude, and more.
The company said that given recent debt restructuring efforts and certain regulatory and payor approvals of its products, it's on track for a strong 2017.
The firm touted recent Blues coverage decisions for the Afirma thyroid cancer test, and final Medicare coverage policies for the Percepta lung cancer test.
Veracyte said that Quest’s access to half of the physicians and hospitals in the US will provide patients with broader access to the Afirma GEC.
The test is designed to analyze the expression of microRNA biomarkers in indeterminate thyroid fine needle aspirate smears in order to differentiate benign thyroid nodules from malignant ones.
Researchers have sequenced the genome of the depth-dwelling giant squid.
Prosecutors have charged a former Drexel University professor with theft for allegedly spending federal grant money on adult entertainment and other unrelated expenses, according to the Philadelphia Inquirer.
Chris Collins, a former US representative, has been sentenced to more than two years in prison in an insider trading case involving an Australian biotechnology firm, the New York Times reports.
In PNAS this week: Trypanosoma brucei transcripts, estimate of people at risk of inherited retinal disease, and more.